

# Early Imaging Eligibility

○ 0 of 6 completed

## Form Instructions

ALL Inclusion questions #1-3 must be "yes" and ALL exclusion questions #1-4 must be "no" for a participant to qualify for participation in PPMI 2.0 Early Imaging. If any of these criteria are not met, please fill out the Early Imaging Screen Fail form in this visit and conclude their participation in PPMI 2.0 Early Imaging.

Assessment Date

10/20/2020



## Inclusion Criteria

1. Enrolled in PPMI 2.0 Clinical protocol.

No

Yes

2. Able to provide informed consent.

No

Yes

3. Women may not be pregnant, lactating or planning pregnancy during the study.

No

Yes

a. Includes a negative serum pregnancy test prior to Baseline 18F-AV-133 injection.

b. Includes a negative urine pregnancy test prior to injection of 18F-AV-133 on day of Baseline PET scan.

c. Women participating in the study must be of non-childbearing potential or be using a highly effective method of birth control 14 days prior to until at least 24 hours after the last injection of 18F-AV-133.

## Exclusion Criteria

1. Received any of the following medications that might interfere with 18F-AV-133 PET imaging: tetrabenazine (TBZ) or methylphenidate, reserpine, or amphetamine derivative, within 1 month prior to the Screening 18F-AV-133 injection.

No

Yes

3. Are currently taking medications that are known to cause QT-prolongation.

No

Yes

4. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.

No

Yes



Parkinson's Disease Inclusion/Exclusion Criteria

Montreal Cognitive Assessment (MoCA)

